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supporting more aggressive IV iron use as 
being safe and eff ective. Th is will no doubt 
accelerate under a bundled payment sys-
tem, but it is extremely unlikely that ESA 
use will decline by the 25 – 50 % predicted 
by some observers. 5 Although PRCA is not 
as much a concern in the United States as 
in Japan, it is not likely there will be a mas-
sive shift  to SC ESA administration under 
a bundled payment system; the overall 
decrease in ESA dose is likely to be similar 
to that in Japan, in the 10 – 20 % range. It will 
take many years for Medicare and other 
analysts to determine whether dialysis 
patients in the United States are better off  
with the lower ESA and higher IV iron 
doses that will inevitably result from eff orts 
at cost conservation. Th e interplay among 
ESA dosing, iron dosing, Hb achieved, cost 
containment, and long-term outcomes 
(survival) is extremely complex and will 
require sophisticated models to elucidate 
( Figure 1 ). It is hoped that the Centers for 
Medicare and Medicaid Services and the 
National Institutes of Health will exploit 
this unique opportunity to perform a struc-
tured analysis of the eff ects of this radical 
change in dialysis reimbursement on ane-
mia management processes and outcomes 
to inform policy makers and providers as 
US health care attempts to transition to a 
culture of comparative eff ectiveness. 
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 Fueling the fire in acute 
kidney injury: endothelial 
cells collect their Toll 
 Timothy A.  Sutton 1 and  Pierre C.  Dagher 1 
 Chen  et al. demonstrate endothelial expression of Toll-like receptor 4 
(TLR4) in the outer medulla of the kidney early in the course of ischemic 
acute kidney injury. Furthermore, they provide data that support the 
hypothesis that activation of endothelial TLR4 in the early extension 
phase of AKI by damage-associated molecular pattern molecules 
released from injured tubules results in endothelial activation. This 
activation can serve to amplify inflammation and tubular damage. 
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 Th ere is a long-standing appreciation that 
altered vascular function contributes to 
decreasing glomerular fi ltration rate dur-
ing acute kidney injury (AKI). Although 
overall renal blood fl ow is only transiently 
diminished following an inciting insult to 
the kidney, there is a more persistent and 
profound (relative to the cortex) decrease 
in outer medullary blood flow that is 
implicitly linked to the complex interplay 
among tubular injury, infl ammation, and 
endothelial alteration. 1 Th is interplay not 
only serves to adversely impact glomeru-
lar fi ltration rate but can also promote 
further tubular-cell injury beyond the 
 initial insult by extending tissue hypoper-
fusion. Activation of infl ammation is an 
important component of both the initia-
tion and the extension of injury in 
ischemic AKI, and enhancement of leu-
kocyte – endothelial interactions is a sali-
ent feature of this process. Interruption of 
the leukocyte – endothelial interaction has 
been an attractive target for therapeutic 
intervention; however, the mechanisms 
of endothelial activation in AKI are 
poorly defi ned. Chen  et al. 2 (this issue) 
shed light on this area by providing evi-
dence that incriminates endothelial Toll-
like receptor 4 (TLR4) in the initiation of 
endothelial-cell activation and further 
implicates the innate immune system 
( Figure 1 ) in the pathophysiology of 
ischemic AKI. 3 
 Th e recognition of TLR4 as the receptor 
for endotoxin more than a decade ago 
revolutionized the fi elds of innate immu-
nity and infectious diseases. TLR4 is one 
of more than a dozen receptors belonging 
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to the TLR superfamily, which are now 
known to play a central role in mammalian 
innate immunity. Th ese receptors detect 
their respective microbial ligands through 
molecular pattern recognition. Th is mech-
anism lacks high specifi city but increases 
the repertoire of each receptor to multiple 
ligands with frequent overlap. Th e infl am-
matory response initiated upon receptor –
 ligand interaction serves as the fi rst line of 
defense against a large spectrum of bacteria, 
fungi, and viruses and is essential for micro-
bial clearance and the subsequent activation 
of the adaptive immune system. However, 
it is also recognized that tissue damage can 
be a by-product of this defensive infl amma-
tory response when severe and prolonged. 
For example, the sepsis syndrome is now 
understood to be in part a manifestation 
of the destructive infl ammatory arm of the 
innate immune response. 4 
 Recently, the fi eld of TLRs and their lig-
ands has witnessed an expansion in both 
location and function. It is now known 
that TLRs are expressed on cells other than 
the traditional members of the innate 
immune system. Th ey have been detected 
in epithelial, endothelial, muscular, and 
neuronal cells, to cite just a few, and may 
in these cells serve functions similar to 
those they perform in innate immune 
cells. Furthermore, the realization that 
endogenous non-microbial ligands can 
also activate these receptors has immensely 
broadened the fi eld beyond infectious dis-
eases. Substances released during tissue 
injury, such as heat shock proteins, high-
mobility group box 1 (HMGB1), and frag-
ments of the extracellular matrix, can 
activate infl ammatory responses through 
TLRs. Consequently, TLRs may serve as 
important monitors of tissue damage and 
modulators of disease in a variety of con-
ditions, such as atherosclerosis, autoim-
mune diseases, and ischemia – reperfusion 
injury (IRI). 
 TLR4 is known to be expressed on renal 
tubular epithelial cells and to respond 
robustly to local and systemic infections. 5 
More recently, it has been demonstrated 
that TLR4 is an important player in 
ischemic AKI. Elegant studies by Wu 
 et al. 6 using chimeric mice specifi cally 
pointed to tubular epithelial TLR4 as an 
important modulator of ischemic AKI. 
Th e article by Chen  et al. 2 now extends 
this role of TLR4 into the endothelium of 
the kidney and furthers our understand-
ing of the complex role these receptors 
play in the kidney. In this study, Chen and 
co-workers used multiple approaches to 
demonstrate that expression of TLR4 
increases in the endothelium of the outer 
medullary peritubular microvasculature 
following IRI. This increase in the 
endothelial TLR4 expression has an appar-
ent peak at 4  h of reperfusion — much ear-
lier than the increase observed at 24  h in 
tubular epithelial cells. Th e authors com-
plement this observation with  in vitro 
studies demonstrating that endothelial 
stressors likely to occur during IRI, 
including production of reactive oxygen 
species, can increase expression of TLR4 
mRNA in isolated microvascular endothe-
lial cells. Th ey further build on this obser-
vation with studies demonstrating that the 
increase in mRNA for a variety of adhe-
sion molecules in microvascular endothe-
lial cells isolated from kidneys 4  h aft er IRI 
is abrogated in endothelial cells isolated 
from  TLR4  – / –  mice. Finally, they demon-
strate that HMGB1 stimulates an increase 
in mRNA for a variety of adhesion mole-
cules in microvascular endothelial cells 
isolated from kidneys of wild-type mice 
but not  TLR4  – / –  mice. In total, these stud-
ies provide evidence for the hypothesis 
that increased expression of TLR4 on 
endothelial cells early in the course of 
ischemic AKI provides fertile ground for 
the activation of endothelial cells by 
endogenous molecules released from 
injured tubules — thus fueling the infl am-
matory fi re of AKI and further extending 
tubular injury. 
 While this study by Chen  et al. 2 brings 
new focus to the role of endothelial Toll 
signaling in the pathophysiology of AKI, it 
also raises some questions. In particular, 
what is the contribution of endothelial TLR 
signaling versus tubular epithelial TLR sig-
naling to the fi nal outcome? Th e temporal 
diff erence in expression during the course 
of ischemic AKI that this study demon-
strates suggests that TLR signaling through 
endothelial cells and tubular epithelial cells 
may be complementary and additive in 
promoting injury. In support of this, 
studies of endothelial TLR4 in other organ 
systems suggest a critical role for endothe-
lial TLR4 in activating endothelium and 
recruiting leukocytes to areas of injury. 7,8 
Further studies in models of AKI using 
mice expressing TLR4 exclusively in the 
endothelium and mice with TLR4 specifi -
cally knocked out of the endothelium 
should provide further clarifi cation of the 
role of endothelial TLR4 in AKI. 
 Another issue raised is the nature of the 
endogenous ligands that stimulate TLR4 
during AKI. As is mentioned above, 
ischemic AKI can produce a variety of 
potential TLR4 ligands. Wu  et al. identi-
fied increased expression of HMGB1, 
hyaluronan, and biglycan 24  h after 
ischemic injury 6 and postulated these as 
potential TLR4 ligands following injury. 
While Chen  et al. 2 used HMGB1 as an 
activating ligand for TLR4 for their 
 in vitro studies of isolated endothelial 
cells, the important activating ligands 
released in the early phases of ischemic 
AKI have not been clarifi ed. Th e observa-
tion that the  TLR4  – / –  mouse appears to be 
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 Figure 1  |  Schematic representation of the interaction among endothelial alterations, innate 
immunity (canonical and non-canonical), and tubular injury in ischemic acute kidney injury. 
This interaction serves to initiate and extend injury that results in diminished glomerular filtration rate. 
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AKI than the  MyD88  – / –  mouse 6,9 suggests 
that both MyD88-dependent and MyD88-
independent pathways are activated by 
TLR4 activation. Th is may also suggest 
diff erent ligand – TLR4 complexes coordi-
nating unique signaling cascades. 10 Th is 
is of potential importance because, as 
Chen  et al. 2 outline,  ‘ each ligand may acti-
vate its own TLR4-receptor complex and 
intracellular signaling pathways ’ and thus 
produce diff erent physiological results. 
Nonetheless, targeting the ligand – TLR4 
interaction may be a more fruitful thera-
peutic endeavor than targeting the down-
stream pathways in ischemic AKI. 
 In conclusion, Chen  et al. 2 have again 
brought the endothelium into the con-
versation as an important therapeutic 
target in AKI. Th e overall understanding 
of non-glomerular endothelial-cell biology 
and how it relates to kidney disease is still 
in a relatively early stage in comparison 
with other organs. Although studies such 
as the one highlighted here continue to 
make strides in our knowledge, there is 
still considerable progress to be made 
before this knowledge can be translated 
into meaningful therapeutic advances 
for AKI. 
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 Angiotensin II: breathtaking 
in the renal medulla 
 Volker H.  Haase 1 
 Angiotensin II (Ang II) is a major contributor to the progression of renal 
fibrosis. Wang and colleagues provide evidence that signaling through 
the prolyl-4-hydroxylase domain (PHD) – hypoxia-inducible factor-1 
(HIF-1) pathway mediates profibrotic effects of Ang II in rat renal 
medullary interstitial cells under normoxic conditions, thus placing the 
HIF oxygen-sensing pathway into the center of an Ang II-induced 
profibrotic signaling cascade. 
 Kidney International (2011)  79, 269 – 271.  doi: 10.1038/ki.2010.434 
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 Aside from its potent hemodynamic 
eff ects, angiotensin II (Ang II) stimulates 
growth of diff erent renal cell types and 
increases the expression and synthesis of 
extracellular matrix proteins and various 
cytokines and chemokines, thus promot-
ing infl ammation and fi brosis. 1 In the con-
text of renal injury, it is a major contributor 
to the progression of chronic kidney dis-
ease. Ang II signals through two specifi c G 
protein-coupled receptors, the Ang II 
receptor type 1 (AT 1 ) and the Ang II recep-
tor type 2 (AT 2 ). Signaling through the 
AT 1 receptor mediates vasoconstriction 
and aldosterone release, stimulates tubular 
sodium transport, and promotes growth, 
infl ammation, and fi brosis, whereas AT 2 
signaling has been proposed to antagonize 
these AT 1 -mediated eff ects and is believed 
to protect from progression of chronic 
 kidney disease. Another major eff ect of 
AT 1 -receptor activation is the generation 
of reactive oxygen species (ROS). This 
occurs predominantly through activation 
of membrane-bound NADPH oxidase, 
which converts NADPH and molecular 
oxygen to NADP   +   and superoxide anions 
(reviewed by Sachse and Wolf  2 ). 
 Now, Wang and colleagues 3 (this issue) 
demonstrate that Ang II-induced ROS 
generation leads to non-hypoxic stabiliza-
tion of the oxygen-sensitive   -subunit of 
hypoxia-inducible factor (HIF)-1 in rat 
renal medullary interstitial cells, which in 
turn is required for Ang II-stimulated col-
lagen I / III and tissue inhibitor of metal-
loproteinases (TIMP)-1 synthesis, thereby 
placing HIF-1 into the center of an Ang 
II-induced profi brotic signaling cascade 
( Figure 1 ). HIF-1  stabilization was, fur-
thermore, necessary for Ang II-induced 
growth and vimentin expression. While 
treatment with Ang II also led to increased 
HIF-2  expression, inactivation of HIF-
2  , in contrast to HIF-1  knockdown, 
did not signifi cantly aff ect Ang II-induced 
TIMP-1 or collagen I / III levels. 
 HIF-1 and HIF-2 are basic helix-loop-
helix transcription factors that consist of 
an oxygen-sensitive   -subunit and a 
